Voyager Therapeutics (NASDAQ:VYGR) Coverage Initiated by Analysts at Cantor Fitzgerald

Equities research analysts at Cantor Fitzgerald initiated coverage on shares of Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) in a report issued on Friday, Marketbeat reports. The brokerage set an "overweight" rating and a $5.73 price target on the stock. Cantor Fitzgerald's price target indicates a potential upside of 5.14% from the stock's current price.

VYGR has been the subject of a number of other research reports. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Leerink Partners started coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They issued an "outperform" rating and a $15.00 price objective for the company. Citigroup initiated coverage on Voyager Therapeutics in a report on Monday, December 2nd. They issued a "buy" rating and a $12.00 price objective for the company. StockNews.com downgraded Voyager Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Finally, Leerink Partnrs upgraded Voyager Therapeutics to a "strong-buy" rating in a report on Wednesday, October 16th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $15.97.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock traded down $0.28 on Friday, reaching $5.45. The company's stock had a trading volume of 615,352 shares, compared to its average volume of 407,542. The company has a market cap of $297.71 million, a price-to-earnings ratio of 7.68 and a beta of 0.93. The business's fifty day moving average price is $6.13 and its 200 day moving average price is $6.84. Voyager Therapeutics has a twelve month low of $5.19 and a twelve month high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the previous year, the firm earned ($0.59) earnings per share. As a group, equities analysts forecast that Voyager Therapeutics will post -0.89 earnings per share for the current year.

Insider Activity at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the firm's stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares of the company's stock, valued at $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 4.53% of the company's stock.

Hedge Funds Weigh In On Voyager Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp increased its stake in shares of Voyager Therapeutics by 17.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 294,420 shares of the company's stock valued at $2,329,000 after purchasing an additional 44,289 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in shares of Voyager Therapeutics by 36.8% in the 2nd quarter. Commonwealth Equity Services LLC now owns 77,905 shares of the company's stock valued at $616,000 after purchasing an additional 20,950 shares during the period. Rhumbline Advisers increased its position in Voyager Therapeutics by 56.0% in the 2nd quarter. Rhumbline Advisers now owns 72,461 shares of the company's stock valued at $573,000 after buying an additional 26,014 shares in the last quarter. Victory Capital Management Inc. increased its position in Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company's stock valued at $102,000 after buying an additional 1,630 shares in the last quarter. Finally, American Century Companies Inc. increased its holdings in Voyager Therapeutics by 32.4% during the 2nd quarter. American Century Companies Inc. now owns 1,019,332 shares of the company's stock worth $8,063,000 after purchasing an additional 249,659 shares in the last quarter. Institutional investors own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.